Y-biologics

Developer of antibodies for the treatment of multiple diseases

placeDaejeon, Daejeon, South Korea calendar_todayFounded 2007 groups57 employees language ybiologics.com

Innovation

45 patent families (13 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 1,908 times.

YearFilings
20174
20186
20199
20209
202114
202219
202311
202414
20258
20262

Investor mix

16 investors on record; lead investors include InterVest; 1 has since exited.

Investor typeCountShare
Venture capital744%
Private equity531%
Other / undisclosed425%
Coming soon